Tigerise, Inc. was established on January 6, 2020 as a joint venture between Accerise, Inc. and Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed”), one of the largest CROs in China. In September 2026, following the acquisition of its shares by Tigermed Japan Co., Ltd., Tigerise became a subsidiary of Tigermed Japan.
Today, Tigermed Japan serves as the parent company of a four-company group comprising Tigerise (execution of China-originated projects), Micron (imaging CRO), and Medical Edge (data management for academic projects). While respecting each company’s strengths and culture, we will deepen collaboration across the group.
In partnership with Tigermed headquarters, we provide an integrated framework for multi-regional clinical trials,
project management, and monitoring. We support Chinese and other Asian clients in their product development in Japan, while simultaneously assisting Japanese clients with their expansion into overseas markets. We aim to be the partner of choice by combining the Group’s proven track record in China and our expertise in Japan.
Tigerise was established on January 6, 2020 as a joint venture between Accerise, Inc., a Japanese CRO, and Tigermed, China’s largest CRO. In September 2026, we embarked on a new chapter as a subsidiary of Tigermed Japan Co., Ltd.
Under our five-year medium-term vision starting in 2027, we will carry forward the expertise, people, and track records of each group company as shared assets, strengthen collaboration as one team in Japan, and establish top-tier execution capabilities in Japan, driven by quality and speed.
From China and Asia to Japan (inbound), and from Japan to overseas (outbound), we aim to hone our expertise in Japan-China cross-border operations, multi-regional clinical trials, imaging, and data management—all centered on the clinical development of medical supplies, medical devices, and SaMD.
As a member of the Tigermed Japan Group, we will bring outstanding products to the Japanese market ahead of the pack and contribute to the advancement of health care. We sincerely appreciate your continued support.
President & CEO
Hiroaki Suzuki
